P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY

• J. D. Soumerai,
• D. Jagadeesh,
• H. Salman,
• F. Samaniego,
• K. Patel,
• A. Stathis,
• N. Reddy,
• V. P. Kenkre,
• A. Asch,
• C. Diefenbach,
• I. S. Lossos,
• D. Persky,
• F. Awan,
• W. Huang,
• K. Vandever,
• A. D. Zelenetz

Affiliations

J. D. Soumerai

1 Massachusetts General Hospital, Boston

D. Jagadeesh

2 Cleveland Clinic, Cleveland

H. Salman

3 Stony Brook University, Stony Brook

F. Samaniego

4 The University of Texas MD Anderson Cancer Center, Houston

K. Patel

5 Swedish Cancer Institute, Seattle, United States of America

A. Stathis

6 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

N. Reddy

7 Vanderbilt University Cancer Center, Nashville

V. P. Kenkre

8 University of Wisconsin Carbone Cancer Center, Madison

A. Asch

9 Oklahoma University Health Sciences Center, Oklahoma City

C. Diefenbach

10 Perlmutter Cancer Center at NYU Langone Health, New York

I. S. Lossos

11 Sylvester Comprehensive Cancer Center, Miami

D. Persky

12 University of Arizona, Tucson

F. Awan

13 University of Texas Southwestern Medical Center, Dallas

W. Huang

14 MEI Pharma, Inc., San Diego

K. Vandever

14 MEI Pharma, Inc., San Diego

A. D. Zelenetz

15 Memorial Sloan Kettering Cancer Center, New York, United States of America